Literature DB >> 19542427

The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone.

Tom J Creed1, Richard W Lee, Paul V Newcomb, Alexandra J di Mambro, Madhuri Raju, Colin M Dayan.   

Abstract

Treatment failure occurs in up to 30% of patients treated with steroids for inflammatory diseases. The aim of this study was to explore the potential role of 21 cytokines in steroid-resistant inflammatory disease and to develop methods to restore steroid sensitivity through cytokine manipulation. The dexamethasone inhibition of lymphocyte proliferation assay correlates with the outcome of steroid therapy in ulcerative colitis (UC) and other inflammatory diseases. Using this assay, PBMC production of 21 cytokines, assayed by cytokine bead array, was correlated with percentage of suppression of proliferation by 10(-6) M dexamethasone (Imax) in 26 healthy volunteers. Effects of the addition of exogenous cytokines to induce steroid resistance in PBMCs from healthy volunteers and cytokine blockade to improve steroid sensitivity in PBMCs from patients with steroid-resistant UC were then explored. Production of IL-1alpha, IL-10, IL-17, IFN-gamma, G-CSF, GM-CSF, TNF-alpha, and IFN-inducible protein 10 (IP-10) correlated significantly with in vitro steroid sensitivity; however, only IL-2 and TNF-alpha reduced steroid sensitivity when added exogenously. Addition of IL-10 enhanced steroid suppression. Immunoneutralization or receptor blockade of IL-2, but not TNF-alpha, IFN-gamma, IL-4, IL-17, or IP-10 increased steroid sensitivity in cells from steroid-resistant UC patients. Neutralization of IL-10 reduced steroid sensitivity. Of the large panel of cytokines studied, IL-2 appears to have the greatest antagonistic effect on the antiproliferative effect of steroids. These data suggest that IL-2 inhibition in vivo may improve the response to steroids in steroid-resistant individuals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542427     DOI: 10.4049/jimmunol.0801998

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Negative effect of immunosuppressive therapy in the performance of the QuantiFERON gold in-tube test in patients with immune-mediated inflammatory diseases.

Authors:  José M Ramos; Mar Masiá; Juan C Rodríguez; Cristina López; Sergio Padilla; Catalina Robledano; Francisco J Navarro-Blasco; Jaime Matarredona; Mariana F García-Sepulcre; Félix Gutiérrez
Journal:  Clin Exp Med       Date:  2012-06-27       Impact factor: 3.984

2.  Preventive and therapeutic effects of tacrolimus in an interleukin-10-deficient mouse model of colitis.

Authors:  Yohei Okada; Noriaki Maeda; Shoji Takakura; Keiji Miyata; Masahiro Koshiba
Journal:  Inflamm Res       Date:  2011-08-10       Impact factor: 4.575

Review 3.  Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease.

Authors:  Sara De Iudicibus; Raffaella Franca; Stefano Martelossi; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

4.  Evaluating the use of cytosine arabinoside for treatment for recurrent canine steroid-responsive meningitis-arteritis.

Authors:  Christian Günther; Frank Steffen; Daniela S Alder; Laura Beatrice; Caroline Geigy; Katrin Beckmann
Journal:  Vet Rec       Date:  2020-02-21       Impact factor: 2.695

5.  Single-cell transcriptomic analysis reveals the immune landscape of lung in steroid-resistant asthma exacerbation.

Authors:  Lingli Wang; Keilah G Netto; Lujia Zhou; Xiaojie Liu; Ming Wang; Guojun Zhang; Paul S Foster; Fuguang Li; Ming Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-12       Impact factor: 11.205

Review 6.  [Perioperative dexamethasone].

Authors:  B Sinner
Journal:  Anaesthesist       Date:  2019-10       Impact factor: 1.041

7.  Healing Field: Using Alternating Electric Fields to Prevent Cytokine Storm by Suppressing Clonal Expansion of the Activated Lymphocytes in the Blood Sample of the COVID-19 Patients.

Authors:  Hamed Abadijoo; Mohammad Ali Khayamian; Mahsa Faramarzpour; Mohammadreza Ghaderinia; Hossein Simaee; Shahriar Shalileh; Seyed Mojtaba Yazdanparast; Bahman Ghabraie; Jalil Makarem; Ramin Sarrami-Forooshani; Mohammad Abdolahad
Journal:  Front Bioeng Biotechnol       Date:  2022-06-02

Review 8.  Variation in glucocorticoid sensitivity and the relation with obesity.

Authors:  Robin Lengton; Anand M Iyer; Eline S van der Valk; Ellen K Hoogeveen; Onno C Meijer; Bibian van der Voorn; Elisabeth F C van Rossum
Journal:  Obes Rev       Date:  2021-11-27       Impact factor: 10.867

9.  Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients.

Authors:  Nikolai V Kuznetsov; Arezou Zargari; Alexander W Gielen; Oliver D von Stein; Eugen Musch; Ragnar Befrits; Robert Lofberg; Petra von Stein
Journal:  BMC Gastroenterol       Date:  2014-04-23       Impact factor: 3.067

10.  Ex vivo stimulation of whole blood as a means to determine glucocorticoid sensitivity.

Authors:  Christopher Burnsides; Jacqueline Corry; Jacob Alexander; Catherine Balint; David Cosmar; Gary Phillips; Jeanette I Webster Marketon
Journal:  J Inflamm Res       Date:  2012-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.